In addition, it is thought that a screening test for measuring the serum level of EBV IgA and IgG antibodies in the correctly determined high risk groups of a population will help much establish the correct basis for the early diagnosis and proper treatment of NPC patients. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.